MétaCan
Menu
Back to cohort
Record W4391545301 · doi:10.1016/j.ebiom.2024.104991

Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis

2024· review· en· W4391545301 on OpenAlexafffund
James Yarmolinsky, Jamie Robinson, Daniela Mariosa, Ville Karhunen, Jian Huang, Niki Dimou, Neil Murphy, Kimberley Burrows, Emmanouil Bouras, Karl Smith‐Byrne, Sarah J. Lewis, Tessel E. Galesloot, Lambertus A. Kiemeney, Sita H. Vermeulen, Paul Martin, Demetrius Albanes, Lifang Hou, Polly A. Newcomb, Emily White, Alicja Wolk, Anna H. Wu, Loı̈c Le Marchand, Amanda I. Phipps, Daniel D. Buchanan, Maria Teresa Landi, Victoria L. Stevens, Neil E. Caporaso, Paul Brennan, Christopher I. Amos, Sanjay Shete, Heike Bickeböller, Angela Risch, Richard Houlston, Stephen Lam, Adonina Tardón, Chu Chen, Stig E. Bojesen, H. E. Wichmann, David C. Christiani, Gad Rennert, Susanne M. Arnold, John K. Field, Olle Melander, Hans Brunnström, Geoffrey Liu, Angeline S. Andrew, Hongbing Shen, Shanbeh Zienolddiny, Kjell Grankvist, Mikael Johansson, M. Dawn Teare, Yun Chul Hong, Jian‐Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Rosalind A. Eeles, Christopher A. Haiman, Zsofia Kote‐Jarai, Fredrick R. Schumacher, Sara Benlloch, Ali Amin Al Olama, Kenneth Muir, Sonja I. Berndt, David V. Conti, Fredrik Wiklund, Stephen J. Chanock, Catherine M. Tangen, Jyotsna Batra, Judith A. Clements, Henrik Grönberg, Nora Pashayan, Johanna Schleutker, Stephanie J. Weinstein, Catharine West, Lorelei A. Mucci, Géraldine Cancel‐Tassin, Stella Koutros, Karina D. Sørensen, Eli Marie Grindedal, David E. Neal, Freddie C. Hamdy, Jenny Donovan, Ruth C. Travis, Robert J. Hamilton, Sue A. Ingles, Barry S. Rosenstein, Yong‐Jie Lu, Graham G. Giles, Robert J. MacInnis, Adam S. Kibel, Ana Vega, Manolis Kogevinas, Kathryn L. Penney, Jong Y. Park, Janet L. Stanfrod, Cezary Cybulski, Børge G. Nordestgaard, Sune F. Nielsen, Hermann Brenner, Christiane Maier, Christopher J. Logothetis, Esther M. John, Manuel R. Teixeira, Susan L. Neuhausen, Kim De Ruyck, Azad Razack, Lisa F. Newcomb, Davor Lessel, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A. Townsend, Jose E. Castelao, Monique J. Roobol, F. Ménégaux, Kay-Tee Khaw, Lisa Cannon‐Albright, Hardev Pandha, Stephen N. Thibodeau, David J. Hunter, Peter Kraft, William J. Blot, Elio Ríboli, Sizheng Steven Zhao, Dipender Gill, Mark P. Purdue, George Davey Smith, Karl‐Heinz Herzig, Marjo‐Riitta Järvelin, Chris Amos, Rayjean J. Hung, Abbas Dehghan, Marc J. Gunter, Richard M. Martin

Bibliographic record

VenueEBioMedicine · 2024
Typereview
Languageen
FieldMedicine
TopicInflammatory Biomarkers in Disease Prognosis
Canadian institutionsLunenfeld-Tanenbaum Research InstitutePublic Health OntarioUniversity of TorontoInstitute of Cancer Research
FundersDepartment of Epidemiology and Biostatistics, University of California, San FranciscoDivision of Cancer Epidemiology and Genetics, National Cancer InstituteNational Institute of Diabetes and Digestive and Kidney DiseasesNational Human Genome Research InstituteNational Heart, Lung, and Blood InstituteSchool of Public Health, Imperial College LondonWageningen University and ResearchInstituto de Salud Carlos IIIMedical Research CouncilCanadian Cancer Society Research InstituteBiobanco VascoJunta de Castilla y LeónXunta de GaliciaWorld Cancer Research FundRegion SkåneNational Institute for Health and Care ResearchCenters for Disease Control and PreventionChonnam National University Hwasun HospitalMemorial Sloan-Kettering Cancer CenterCentre International de Recherche sur le CancerInstitut National Du CancerNational Health and Medical Research CouncilDeutsche KrebshilfeKarolinska InstitutetAssociazione Italiana per la Ricerca sul CancroUniversity of Maryland School of Public HealthConseil Régional des Pays de la LoireVetenskapsrådetLigue Contre le CancerCanadian Institutes of Health ResearchEuropean CommissionKnut och Alice Wallenbergs StiftelseNational Institute of Environmental Health SciencesSwedish Cancer FoundationMinistry of Health, Labour and WelfareUniversity Hospitals Bristol NHS Foundation TrustConsejería de Educación, Junta de Castilla y LeónMutuelle Générale de l'Education NationaleMinisterie van Volksgezondheid, Welzijn en SportCancerfondenFundación Científica Asociación Española Contra el CáncerMinisterio de Economía y CompetitividadNational Center for Advancing Translational SciencesBundesministerium für Bildung und ForschungAcademy of FinlandCancer Council VictoriaMedizinische Universität GrazInstitut Gustave-RoussyHerzfelder'sche FamilienstiftungGrantová Agentura České RepublikyEmory UniversityVicHealthFlorida Department of HealthNational Institutes of HealthDivision of Cancer Prevention, National Cancer InstituteGroupement des Entreprises Françaises dans la lutte contre le CancerAssociation Anne de Bretagne GenetiqueCentre Hospitalier Universitaire de NantesNIHR Imperial Biomedical Research CentreUniverzita Karlova v PrazeMcGill UniversityOntario Research FoundationGeneralitat de CatalunyaImperial College LondonFood Standards AgencyNational Cancer InstituteEuropean Regional Development FundEuropean Cooperation in Science and TechnologyGénome QuébecInstitut National de la Santé et de la Recherche MédicaleMatthias Lackas-StiftungMoffitt Cancer CenterUmeå UniversitetChonnam National UniversityCentres de Recerca de CatalunyaConsejería de Salud y Familias, Junta de AndalucíaCanadian Cancer SocietyJohns Hopkins UniversityNational Institute on AgingNIHR Bristol Biomedical Research CentreOffice of Research Infrastructure Programs, National Institutes of HealthState of MarylandÖsterreichische ForschungsförderungsgesellschaftUniversity of South FloridaAmerican Institute for Cancer ResearchMinisterstvo Zdravotnictví Ceské RepublikyPelotoniaDeutsche ForschungsgemeinschaftUniversity of IowaNational Cancer CenterOntario Ministry of Research, Innovation and ScienceDeutsches KrebsforschungszentrumHarvard T.H. Chan School of Public HealthKræftens BekæmpelseVictorian Cancer AgencyUniversity of CambridgeStockholms Läns LandstingUniversity of PittsburghLung Cancer Research FoundationMike and Josie Harper Cancer Research InstituteNational Heart and Lung InstituteEno Scientific FoundationAgència de Gestió d'Ajuts Universitaris i de RecercaVersus ArthritisMaryland Department of HealthNational Research CouncilMarshfield Clinic Research FoundationAlbert Einstein Cancer CenterCancer Research UKXarxa de Bancs de Tumors de CatalunyaWorld Health OrganizationWereld Kanker Onderzoek FondsBrigham and Women's HospitalKarl-Franzens-Universität GrazUniversity of BristolDamon Runyon Cancer Research FoundationU.S. Department of Health and Human ServicesAmerican Cancer Society
KeywordsMendelian randomizationMedicineCancerOncologyBioinformaticsGeneticsInternal medicineBiologyGenotypeGeneGenetic variants

Abstract

fetched live from OpenAlex

Background Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. Methods We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry. We then used combined cis -Mendelian randomization and colocalisation analysis to evaluate the causal role of 66 circulating inflammatory markers in risk of 30 adult cancers in 338,294 cancer cases and up to 1,238,345 controls. Genetic instruments for inflammatory markers were constructed using genome-wide significant ( P < 5.0 × 10 −8 ) cis -acting SNPs (i.e., in or ±250 kb from the gene encoding the relevant protein) in weak linkage disequilibrium (LD, r 2 < 0.10). Effect estimates were generated using inverse-variance weighted random-effects models and standard errors were inflated to account for weak LD between variants with reference to the 1000 Genomes Phase 3 CEU panel. A false discovery rate (FDR)-corrected P -value (" q -value") <0.05 was used as a threshold to define "strong evidence" to support associations and 0.05 ≤ q -value < 0.20 to define "suggestive evidence". A colocalisation posterior probability (PPH 4 ) >70% was employed to indicate support for shared causal variants across inflammatory markers and cancer outcomes. Findings were replicated in the FinnGen study and then pooled using meta-analysis. Findings We found strong evidence to support an association of genetically-proxied circulating pro-adrenomedullin concentrations with increased breast cancer risk (OR: 1.19, 95% CI: 1.10–1.29, q -value = 0.033, PPH 4 = 84.3%) and suggestive evidence to support associations of interleukin-23 receptor concentrations with increased pancreatic cancer risk (OR: 1.42, 95% CI: 1.20–1.69, q -value = 0.055, PPH 4 = 73.9%), prothrombin concentrations with decreased basal cell carcinoma risk (OR: 0.66, 95% CI: 0.53–0.81, q -value = 0.067, PPH 4 = 81.8%), and interleukin-1 receptor-like 1 concentrations with decreased triple-negative breast cancer risk (OR: 0.92, 95% CI: 0.88–0.97, q -value = 0.15, PPH 4 = 85.6%). These findings were replicated in pooled analyses with the FinnGen study. Though suggestive evidence was found to support an association of macrophage migration inhibitory factor concentrations with increased bladder cancer risk (OR: 2.46, 95% CI: 1.48–4.10, q -value = 0.072, PPH 4 = 76.1%), this finding was not replicated when pooled with the FinnGen study. For 22 of 30 cancer outcomes examined, there was little evidence ( q -value ≥0.20) that any of the 66 circulating inflammatory markers examined were associated with cancer risk. Interpretation Our comprehensive joint Mendelian randomization and colocalisation analysis of the role of circulating inflammatory markers in cancer risk identified potential roles for 4 circulating inflammatory markers in risk of 4 site-specific cancers. Contrary to reports from some prior conventional epidemiological studies, we found little evidence of association of circulating inflammatory markers with the majority of site-specific cancers evaluated. Funding Cancer Research UK (C68933/A28534, C18281/A29019, PPRCPJT∖100005), World Cancer Research Fund (IIG_FULL_2020_022), National Institute for Health Research (NIHR202411, BRC-1215-20011), Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4), Academy of Finland Project 326291, European Union's Horizon 2020 grant agreement no. 848158 (EarlyCause), French National Cancer Institute (INCa SHSESP20, 2020-076), Versus Arthritis (21173, 21754, 21755), National Institutes of Health (U19 CA203654), National Cancer Institute (U19CA203654).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.712
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0020.003
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.332
Teacher spread0.314 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations46
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueEBioMedicineSame topicInflammatory Biomarkers in Disease PrognosisFrench-language works237,207